Barry Butler is an experienced leader with over 27 years of pharmaceutical experience. Since 2010, Barry has served as CEO of Point Guard Partners, LLC. At Point Guard, Barry has overseen the formation and management of a number of affiliate companies, including Oculos Clinical Research,LLC, Clermont, Inc., Revitalid, Inc., and Kurobe Pharmaceuticals, Inc.
Prior to founding Point Guard Partners, Barry held numerous executive positions in healthcare companies. In 2004, Barry co-founded Rx Development Resources, LLC, an ophthalmic CRO that later became Sirion Therapeutics, Inc, a successful ophthalmic pharmaceutical company. Barry served as President and CEO of Sirion until its sale in 2010. Prior to founding Sirion, Barry was the first Global Category Leader for Pharmaceuticals at Bausch & Lomb, and held sales and marketing management positions at AcSentient, Inc. and Glaxo, Inc.
Barry has raised over $130 million in private financing since 2006 and has led exit transactions totaling more than $350 million. He holds a bachelor’s degree in finance from The University of Alabama and a Master of Business Administration degree from City University of Seattle.